Table 4.
Differentially Abundant Bacterial Amplicon Sequence Variants in SARS-CoV-2–Infected Participants With and Without Respiratory Symptoms in GJAM Analyses
| ASV | Bacterial Species | Age | SARS-CoV-2 Respiratory Symptoms | Age × SARS-CoV-2 Respiratory Symptoms | |||
|---|---|---|---|---|---|---|---|
| Estimate | (95% CI) | Estimate | (95% CI) | Estimate | (95% CI) | ||
| 336 | Moraxella lincolnii | −.006 | (−.008, −.004) | −.081 | (−.111, −.051) | .007 | (.004, .009) |
| 339 | Moraxella lincolnii | −.002 | (−.003, −.0008) | −.018 | (−.032, −.004) | .002 | (.0003, .003) |
| 692 | Prevotella intermedia | NS | NS | .024 | (.008, .039) | −.002 | (−.003, −.0002) |
| 1283 | Fusobacterium nucleatum | .003 | (.0009, .005) | .038 | (.008, .067) | −.004 | (−.007, −.002) |
| 1519 | Streptococcus pyogenes | NS | NS | .043 | (.002, .071) | NS | NS |
| 2155 | Mycoplasma lipophilum | −.001 | (−.002, −.0003) | −.014 | (−.027, −.001) | NS | NS |
Abbreviations: ASV, amplicon sequence variant; CI, confidence interval; GJAM, generalized joint attribute modeling; NS, not significant; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.